Biotech funding program
This grant funds biotech companies developing cell and gene therapies for glioblastoma or pancreatic cancer, focusing on strong science and clear clinical translation.
This grant is no longer accepting proposals
Alliance for Cancer Gene Therapy has archived this opportunity.
Funder: Alliance for Cancer Gene Therapy
Due Dates: Rolling
Funding Amounts: Amount varies by project; funding goal and budget are proposed by applicant.
Summary: Supports biotech companies developing cell and gene therapies for glioblastoma and pancreatic cancer with strong clinical potential.
Key Information: Only biotech companies (private or public) are eligible; proposals must focus on glioblastoma or pancreatic cancer.
Description
The Alliance for Cancer Gene Therapy's Biotech Funding Program is designed to accelerate the development of cell and gene therapies targeting glioblastoma and pancreatic cancer—two solid tumor types with significant unmet clinical needs and limited investment. The program seeks projects with robust scientific foundations and clear clinical translation pathways, offering both the potential for meaningful patient benefit and financial sustainability to support further innovation. Guided by a prominent Scientific Advisory Council and Board of Directors, the program prioritizes high-impact, underfunded cancer types that face substantial barriers to clinical trial success and venture capital support.
